DNA-PK inhibitors for treatment of cancer

US9878993B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Paul S. Charifson · Framingham, US
• Kevin Michael Cottrell · Cambridge, US
• Hongbo Deng · Southborough, US
• John P. Duffy · Westborough, US
• Huai Gao · Arlington, US
• Simon Giroux · Cambridge, US
• Jeremy Green · Waltham, US
• Katrina Lee Jackson · Cambridge, US
• Joseph M. Kennedy · Walpole, US
• David J. Lauffer · Saline, US
• Mark Ledeboer · Acton, US
• Pan Li · Lexington, US
• John Patrick Maxwell · Hingham, US
• Mark A. Morris · Somerville, US
• Albert Pierce · Cambridge, US
• Nathan D. Waal · Cambridge, US
• Jinwang Xu · Framingham, US

Key dates

• Filing date: May 19, 2016
• Grant date: Jan 30, 2018
• Expiry date: May 19, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D521/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.